Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-13-1547 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-13-1547 C3980586!3980586!24536059     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Cancer+Res 2014 ; 20 (7): 1741-6 Nephropedia Template TP {{tp|p=24536059|t=2014. Molecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cancer |pdf=|usr=}}{{24536059}} gab.com Text Molecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cancer JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24536059 #FOAvip SIRT7 belongs to the Sirtuin family of NAD-dependent enzymes, whose members play diverse roles in aging, metabolism, and disease biology. Increased SIRT7 expression is observed in human cancers, and growing evidence suggests important SIRT7 functions in fundamental cellular programs that impact on oncogenic transformation and tumor biology. SIRT7 associates with chromatin, where it catalyzes selective deacetylation of lysine 18 on histone H3 (H3K18), an emerging epigenetic biomarker of aggressive tumors and poor clinical outcome in cancer patients. Through H3K18 deacetylation at specific promoters, SIRT7 controls a tumor suppressive gene expression program that stabilizes the transformed state of cancer cells. SIRT7 also orchestrates several molecular processes, including rRNA and tRNA synthesis, which ultimately promote the increased ribosome biogenesis necessary for tumor cell growth and proliferation. Remarkably, inactivation of SIRT7 can reverse the transformed phenotype of cancer cells and reduce their tumorigenicity in vivo. These findings place SIRT7 at the crossroads of chromatin signaling, metabolic, and tumor-regulatory pathways. Thus, SIRT7 is a promising pharmacologic target for epigenetic cancer therapy. The development of SIRT7 modulators may allow new therapeutic strategies that control tumor progression by reprogramming the chromatin landscape and biosynthetic machinery of cancer cells. Twit Text FOAVip Molecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cancer ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24536059 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24536059 #FOAvip English Wikipedia <ref>{{Cite pmid|24536059}}</ref> Molecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cancer #MMPMID24536059 Paredes S; Villanova L; Chua KF Clin Cancer Res 2014[Apr]; 20 (7): 1741-6 PMID24536059show ga SIRT7 belongs to the Sirtuin family of NAD-dependent enzymes, whose members play diverse roles in aging, metabolism, and disease biology. Increased SIRT7 expression is observed in human cancers, and growing evidence suggests important SIRT7 functions in fundamental cellular programs that impact on oncogenic transformation and tumor biology. SIRT7 associates with chromatin, where it catalyzes selective deacetylation of lysine 18 on histone H3 (H3K18), an emerging epigenetic biomarker of aggressive tumors and poor clinical outcome in cancer patients. Through H3K18 deacetylation at specific promoters, SIRT7 controls a tumor suppressive gene expression program that stabilizes the transformed state of cancer cells. SIRT7 also orchestrates several molecular processes, including rRNA and tRNA synthesis, which ultimately promote the increased ribosome biogenesis necessary for tumor cell growth and proliferation. Remarkably, inactivation of SIRT7 can reverse the transformed phenotype of cancer cells and reduce their tumorigenicity in vivo. These findings place SIRT7 at the crossroads of chromatin signaling, metabolic, and tumor-regulatory pathways. Thus, SIRT7 is a promising pharmacologic target for epigenetic cancer therapy. The development of SIRT7 modulators may allow new therapeutic strategies that control tumor progression by reprogramming the chromatin landscape and biosynthetic machinery of cancer cells. äMolecular Pathways: Emerging Roles of Mammalian Sirtuin SIRT7 in Cance(epmc).pdf DeepDyve Pubget Overpricing